Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (181)	12/7/2001 6:52:21 AM
From: nigel bates	Respond to of 469

The PR itself - Oxford, UK, 7 December 2001 - Oxford GlycoSciences Plc (LSE: OGS; NASDAQ: OGSI) today announced that it has achieved its goal to discover and file patent applications for over 4,000 disease-associated proteins, protein isoforms and their genes. This goal has been achieved by applying OGS' industrialised proteomics platform to the analysis of clinical and cellular materials. The patent portfolio focuses on disease areas with major unmet clinical needs, including breast, liver, pancreatic and other cancers and CNS diseases such as schizophrenia and dementia. The knowledge of proteins involved in disease processes can provide new insights and approaches to drug discovery, by speeding-up the identification and selection of new drug targets. Raj Parekh, OGS' Chief Scientific Officer said: 'By exploiting our leading proteomics platform, we have been the first to discover a substantial number of disease-associated proteins. By concentrating principally on proteins in relevant cells, tissues and fluids, we avoid so much of the ambiguity inherent in a genomics-only approach and can discover the protein molecules that are altered in clinical samples from patients with specific diseases.' OGS is focused on building a large number of drug discovery programmes targeted against this disease-associated protein portfolio. The Company is pursuing a broad ranging drug discovery strategy covering small molecules through its partnership with NeoGenesis as well as therapeutic antibodies through its alliance with Medarex/Genmab. Michael Kranda, OGS' Chief Executive Officer said: 'We believe that this is the largest single disease-associated protein patent portfolio. We see it as a major corporate asset which constitutes the foundation on which we are building multiple internal drug discovery programmes.' A webcast presentation, hosted by Dr. Raj Parekh, OGS' Chief Scientific Officer, will discuss the value of this protein portfolio in different examples of OGS research programmes. To access the presentation, please log on to www.ogs.com at 10.00am (GMT). A recorded replay will be available from 2.00pm (GMT)...